Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06380647
Status:
COMPLETED
Last Update Posted:
2024-04-24
First Post:
2024-03-31
Brief Title:
Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns
Sponsor:
King Edward Medical University
Organization:
King Edward Medical University
Study Overview
Official Title:
Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
childburn
Brief Summary:
Introduction Early detection is important in treating patients with Eczema Herpeticum EH which may arise in paediatric burn patients As soon as a clinical diagnosis is confirmed antiviral medications should be started to ensure an early resolution of the disease Several studies have indicated that acyclovir is the best treatment for EH lesions in the majority of individuals
Objective Compare efficacy of the prophylactic acyclovir and placebo in preventing eczema Herpeticum in paediatric burn patients
Objective Compare efficacy of the prophylactic acyclovir and placebo in preventing eczema Herpeticum in paediatric burn patients
Detailed Description:
Materials and Methods Study design Randomised control trial Setting Pediatric burn unit Mayo hospital Lahore Duration 1st October 2019 to 30th September 2020 Data collection procedure All the patients were managed with intravenous fluids antibiotics antipyretics and hydrocolloid dressing as per ward routine management protocol along with prophylactic acyclovir and placebo On the zero day of admission after parents provided informed consent patients were randomly assigned to one of two groups using a computer-generated table Group A patients were given intra venous acyclovir divided into three doses for 7 to 14 days during their stay Group B patients were given 15 intravenous Hypertonic sodium chloride divided into three doses as placebo for 7 to 14 days so that parents could be blinded to group allocation Patients were observed for developing signs of eczema Herpeticum and Tzanck smear was done every 10th day and first follow up at outpatient department after 7days of discharge
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None